Andrew Zupnick, PhD
Vice President, Therapeutic Strategy, Oncology
Andrew Zupnick, PhD, has more than 25 years of experience focused exclusively in oncology. As Vice President of Therapeutic Strategy for Oncology at Worldwide, he supports study optimization, delivery oversight, training, and the development of new initiatives across commercial and operational teams, helping ensure Worldwide remains at the forefront of industry trends and emerging oncology therapies.
Ask Dr. Zupnick a question
Submit an RFP. Ask a Question
A cell and molecular biologist by training, Andrew holds a PhD, MS, and MA from Columbia University, as well as a BS from MIT. He brings a broad and integrated perspective to oncology drug development, informed by two decades of leadership experience spanning both commercial and operational roles within specialty oncology CROs.
Andrew began his career at Prologue Research, a niche oncology CRO founded from what later became The James Cancer Center at The Ohio State University. Following Prologue’s acquisition by Novella Clinical in 2010, and Novella’s subsequent acquisition by Quintiles, Andrew established and led the global oncology strategy team within the standalone biotech CRO business, later rebranded as IQVIA Biotech in 2019.
In this role, he partnered with biopharmaceutical companies around the world to design and execute oncology development strategies across a wide range of tumor types and development stages, from early-phase programs through registrational studies.
In 2020, Andrew joined Catalyst Clinical Research to help build its oncology specialty CRO business. Following Catalyst’s integration with Worldwide Clinical Trials in 2026, he continues to help oncology sponsors navigate the complexities of global drug development through strategic guidance, therapeutic expertise, and deep operational insight.
